Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes - PubMed
5 hours ago
- #kidney outcomes
- #GLP-1 receptor agonists
- #type 2 diabetes
- The study found no significant differences among dulaglutide, exenatide, liraglutide, and semaglutide in the primary kidney composite outcome (incident CKD stages 3-4 and kidney failure).
- Semaglutide showed reduced risk compared to dulaglutide and exenatide for the secondary kidney composite outcome (including death from any cause), with hazard ratios of 0.92 and 0.88, respectively.
- Compared to dulaglutide, semaglutide was associated with a reduced risk of death (HR 0.81).
- The study utilized a retrospective observational design with target trial emulation and inverse probability of treatment weighting to compare GLP-1 receptor agonists in adults with type 2 diabetes and moderate cardiovascular risk.
- Limitations include potential residual confounding, lack of HbA1c and weight data, and uncertainty about prescription indications, suggesting semaglutide may be preferred for delaying or preventing CKD in this population.